目的 探討阿托伐他汀鈣聯(lián)合硫酸氫氯吡格雷對(duì)冠狀動(dòng)脈病變的影響。方法 2013年8月-2017年1月選擇在南通市腫瘤醫(yī)院診治的急性冠狀動(dòng)脈綜合征患者122例，根據(jù)隨機(jī)信封抽簽原則平均分為觀察組與對(duì)照組各61例，兩組都給予經(jīng)皮冠狀動(dòng)脈介入治療，對(duì)照組給予硫酸氫氯吡格雷輔助治療，觀察組給予阿托伐他汀鈣聯(lián)合硫酸氫氯吡格雷輔助治療，都治療觀察4周。比較兩組臨床療效，在治療前后采用超聲測(cè)量左室舒張末內(nèi)徑（LVEDD）、左室收縮末內(nèi)徑（LVESD）變化，采用免疫熒光標(biāo)記法測(cè)定血小板膜糖蛋白Ⅱb/Ⅲa（GPⅡb/Ⅲa）。結(jié)果 觀察組的治療總有效率為96.7%，對(duì)照組為82.0%，觀察組的總有效率明顯高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組與對(duì)照組治療后的左室舒張末內(nèi)徑（LVEDD）、左室收縮末內(nèi)徑（LVESD）值都明顯低于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；同時(shí)治療后觀察組的LVEDD和LVESD值也明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組與對(duì)照組治療后的GPⅡb/Ⅲa值分別為（10.22±3.12）%和（14.32±2.98）%，都明顯低于治療前的（20.98±3.30）%和（21.22±2.98）%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組也明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。所有患者隨訪6個(gè)月，觀察組的心律失常、出血與死亡等發(fā)生率為3.3%，對(duì)照組為19.7%，觀察組明顯少于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 阿托伐他汀鈣和硫酸氫氯吡格雷在急性冠狀動(dòng)脈綜合征治療中的應(yīng)用能提高心功能，降低GPⅡb/Ⅲa的表達(dá)，從而提高近期與遠(yuǎn)期療效。

Objective To investigate the effects of atorvastatin and clopidogrel on coronary artery disease. Methods From August 2013 to January 2017, 122 patients of acute coronary syndrome in our hospital for diagnosis and treatment were selected as the research object, all the patients were divided into observation group and control group of 61 case accorded to the random lottery envelopes randomly, two groups were treated with percutaneous coronary artery interventional therapy, the control group was given clopidogrel bisulfate adjuvant therapy, the observation group was given atorvastatin atorvastatin calcium and clopidogrel adjuvant therapy, all patients were observed for 4 weeks. Results The total effective rate of the observation group was significantly higher than that of the control group (P < 0.05). The LVEDD and LVESD values of the observation group and the control group after treatment were significantly lower than those before treatment (P < 0.05), while the LVEDD and LVESD values in the observation group were significantly lower than those in the control group (P < 0.05). The platelet membrane glycoprotein GP Ⅱb/Ⅲa values in the observation group and the control group after treatment were (10.22 ±3.12)% and (14.32 ±2.98)% that were significantly lower than those before treatment of (20.98 ±3.30)% and (21.22 ±2.98)%, the observation group was significantly lower than the control group (P < 0.05). All patients were followed up for 6 months, the incidence of arrhythmia, bleeding and death in the observation group was 3.3%, so that was 19.7% in the control group, and the observation group was less than that of the control group (P < 0.05). Conclusion Atorvastatin atorvastatin calcium and clopidogrel adjuvant in patients with acute coronary syndrome therapy can improve heart function, reduce the expression of platelet membrane glycoprotein GP Ⅱb/Ⅲa, so as to improve the short-term and long-term efficacy.